Cite

HARVARD Citation

    Caffo, O. et al. (2014). Potential value of rapid prostate-specific antigen decline in identifying primary resistance to abiraterone acetate and enzalutamide. Future oncology. pp. 985-993. [Online]. 
  
Back to record